ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:45AM-11:00AM: Abstract Number: 0882

Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II (0879–0884)

10:45AM-11:00AM: Abstract Number: 0888

TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)

11:00AM-11:15AM: Abstract Number: 0895

Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)

11:00AM-11:15AM: Abstract Number: 0889

Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)

11:00AM-11:15AM: Abstract Number: 0883

Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II (0879–0884)

11:00AM-11:15AM: Abstract Number: 0865

Spatial Transcriptomic Analysis of Calcinosis Cutis in Dermatomyositis Uncovers Disease-Associated Pathways Involving IL-6, Tissue Remodeling, and Osteopontin

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II: Basic & Translational Research (0861–0866)

11:00AM-11:15AM: Abstract Number: 0871

The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes

Abstracts: Rheumatoid Arthritis – Animal Models (0867–0872)

11:00AM-11:15AM: Abstract Number: 0877

Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)

11:00AM-11:15AM: Abstract Number: 0859

Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps

Abstracts: Antiphospholipid Syndrome (0855–0860)

11:15AM-11:30AM: Abstract Number: 0860

Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository

Abstracts: Antiphospholipid Syndrome (0855–0860)

11:15AM-11:30AM: Abstract Number: 0896

Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)

11:15AM-11:30AM: Abstract Number: 0878

Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)

11:15AM-11:30AM: Abstract Number: 0890

Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)

11:15AM-11:30AM: Abstract Number: 0866

Immunoglobulin from sera of patients with myositis can passively enter cultured human endothelial cells

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II: Basic & Translational Research (0861–0866)

11:15AM-11:30AM: Abstract Number: 0884

Risk Score for Early Mortality to stratify for Intensive SSc Therapy

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II (0879–0884)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].